Solvay Cilansetron NDA "Not Approvable" For Irritable Bowel Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
The "not approvable" letter requests additional clinical trials as well as changes to some non-clinical items, Solvay says. The company says it has informed FDA of its intent to amend the application.
You may also be interested in...
Solvay Withdraws NDA For IBS Agent Cilansetron
The company points to the burden of additional clinical work requested by FDA and a weak potential market for the irritable bowel syndrome product.
Solvay Withdraws NDA For IBS Agent Cilansetron
The company points to the burden of additional clinical work requested by FDA and a weak potential market for the irritable bowel syndrome product.
Solvay Preparing Announcement On Cilansetron NDA
Solvay receives a response letter from FDA one week ahead of the user fee deadline for the irritable bowel syndrome product. Solvay is currently assessing the letter's contents, the company says.